Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Yasuteru Kondo"'
Autor:
Junji Furuse, Namiki Izumi, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, Katsuaki Motoyoshi, Masatoshi Kudo
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 2, Pp 195-205 (2023)
Abstract Background Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial to evaluate th
Externí odkaz:
https://doaj.org/article/1586272cd8f54a5590c0cca0a2b18019
Autor:
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai
Publikováno v:
Liver Cancer (2023)
Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, th
Externí odkaz:
https://doaj.org/article/48f623fe69374965a18cf38cb68f57fa
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Alternative treatment modalities are necessary because of the low response rates and unsuitability of molecular-targeted agents (MTA) and/or immune checkpoint inhibitors (iCIs) in HCC patients. Therefore, we analyzed whether drug-eluting bea
Externí odkaz:
https://doaj.org/article/2c2f6b43b78c4decbf6542cdde471b79
Autor:
Yasuteru Kondo, Junichi Akahira, Tatsuki Morosawa, Yukihiro Toi, Akashi Endo, Hiroaki Satio, Mareyuki Endo, Shunichi Sugawara, Yasuhito Tanaka
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract It has been reported that various kinds of immune checkpoint inhibitors (iCIs) could induce immune-related liver damage. We should focus on the programmed cell death-receptor-1 (PD-1) antibody and non-small cell lung cancer (NSCLC) to analyz
Externí odkaz:
https://doaj.org/article/15e200a3a93d41609ec915336caefa62
Autor:
Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka
Publikováno v:
Cancers, Vol 15, Iss 5, p 1568 (2023)
We retrospectively evaluated the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev), including the interruption or discontinuation of both Atezo and Bev, and the reduction or discontinuation of Bev,
Externí odkaz:
https://doaj.org/article/01c328058d684571b4bb96fa0efddc9d
Autor:
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kazuo Okumoto, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Yasuhiro Takikawa, Takuji Torimura, Tomokazu Matsuura, Masatoshi Ishigami, Kazuhiko Koike, Hitoshi Yoshiji
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 6, p 1571 (2022)
Background: Rifaximin is commonly used for hepatic encephalopathy (HE). However, the effects of long-term treatment for Japanese people are limited. Therefore, this study aimed to investigate the effects and safety of long-term treatment with rifaxim
Externí odkaz:
https://doaj.org/article/b231735f1f094e809ce497a213c10038
Autor:
Chia-Lin Chen, Jeffrey Y. Huang, Chun-Hsiang Wang, Stanley M Tahara, Lin Zhou, Yasuteru Kondo, Joel Schechter, Lishan Su, Michael M C. Lai, Takaji Wakita, François-Loïc Cosset, Jae U Jung, Keigo Machida
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-17 (2017)
Infection of B cells by hepatitis C virus (HCV) is poorly understood, but is thought to result in lymphoproliferative disorders. Here, Chenet al. identify CD86 as co-receptor for lymphotropic HCV and show that HCV infection inhibits memory B-cell fun
Externí odkaz:
https://doaj.org/article/1991ac8957f64473b697653d17ea07e4
Autor:
Yasuteru Kondo, Tooru Shimosegawa
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 2, Pp 3307-3322 (2015)
The adaptive immune system, including type1 helper T cells (Th1 cells), cytotoxic T lymphocytes (CTLs), and dendritic cells (DCs), plays an important role in the control of hepatitis B virus (HBV). On the other hand, regulatory T cells (Tregs) and my
Externí odkaz:
https://doaj.org/article/d3015a0065104b2fbd7cdc2f9c0914b7
Autor:
Yasuteru Kondo, Masashi Ninomiya, Osamu Kimura, Keigo Machida, Ryo Funayama, Takeshi Nagashima, Koju Kobayashi, Eiji Kakazu, Takanobu Kato, Keiko Nakayama, Michael M C Lai, Tooru Shimosegawa
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e98521 (2014)
Various kinds of autoimmune diseases have been reported to have a significant relationship with persistent hepatitis c virus (HCV) infection and Th17 cells. Previously, our group reported that the existence of HCV in T lymphocytes could affect the de
Externí odkaz:
https://doaj.org/article/53c400fd0106417283a5f2c61a01d42c
Autor:
Masashi Ninomiya, Yasuteru Kondo, Ryo Funayama, Takeshi Nagashima, Takayuki Kogure, Eiji Kakazu, Osamu Kimura, Yoshiyuki Ueno, Keiko Nakayama, Tooru Shimosegawa
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66086 (2013)
BACKGROUND AND AIMS: MicroRNAs are small endogenous RNA molecules with specific expression patterns that can serve as biomarkers for numerous diseases. However, little is known about the expression profile of serum miRNAs in PBC. METHODS: First, we e
Externí odkaz:
https://doaj.org/article/5322e71c547543dda8db27b7cf1278ef